author-photo

Eleftherios P. Mamounas

Orlando Health
University of Florida Health
Aultman Hospital

322

Papers

39328

Citations

Citation Trend

Filter By

Papers (222) Sort By

Journal Conference Others

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006).

2021 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 532: Association of pCR and the 8-gene signature: NRG Oncology/NSABP B-41

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE.

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (5)
MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice.

2021 JNCI Cancer Spectrum
Show All
- Source
- Cite
- Save
Citations (0)
Axillary Staging in the Setting of a Preoperative Diagnosis of Ductal Cancer In Situ (DCIS) : Results of an International Expert Panel and a Critical Guideline Performance Using Frequentist and Bayesian Analysis

2020 Annals of Surgical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
248TiP A randomized, double-blind, phase III trial of neoadjuvant chemotherapy (NACT) with atezolizumab/placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant continuation of atezolizumab/placebo (GeparDouze)

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.

2020 Cancer
Show All
- Source
- Cite
- Save
Citations (3)